516 related articles for article (PubMed ID: 12702566)
1. Population pharmacokinetics of the photodynamic therapy agent 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a in cancer patients.
Bellnier DA; Greco WR; Loewen GM; Nava H; Oseroff AR; Pandey RK; Tsuchida T; Dougherty TJ
Cancer Res; 2003 Apr; 63(8):1806-13. PubMed ID: 12702566
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacokinetics of the PDT photosensitizers porfimer sodium (Photofrin), 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a (Photochlor) and 5-ALA-induced protoporphyrin IX.
Bellnier DA; Greco WR; Loewen GM; Nava H; Oseroff AR; Dougherty TJ
Lasers Surg Med; 2006 Jun; 38(5):439-44. PubMed ID: 16634075
[TBL] [Abstract][Full Text] [Related]
3. Mild skin photosensitivity in cancer patients following injection of Photochlor (2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a; HPPH) for photodynamic therapy.
Bellnier DA; Greco WR; Nava H; Loewen GM; Oseroff AR; Dougherty TJ
Cancer Chemother Pharmacol; 2006 Jan; 57(1):40-5. PubMed ID: 16001178
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and clinical effects of mono-L-aspartyl chlorin e6 (NPe6) photodynamic therapy in adult patients with primary or secondary cancer of the skin and mucosal surfaces.
Chan AL; Juarez M; Allen R; Volz W; Albertson T
Photodermatol Photoimmunol Photomed; 2005 Apr; 21(2):72-8. PubMed ID: 15752124
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of pyropheophorbide-a-hexyl ether in the dog.
Payne JT; McCaw DL; Casteel SW; Frazier D; Rogers K; Tompson RV
Lasers Surg Med; 1996; 18(4):406-9. PubMed ID: 8732580
[TBL] [Abstract][Full Text] [Related]
6. Localization and treatment of transformed tissues using the photodynamic sensitizer 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a.
Furukawa K; Yamamoto H; Crean DH; Kato H; Mang TS
Lasers Surg Med; 1996; 18(2):157-66. PubMed ID: 8833284
[TBL] [Abstract][Full Text] [Related]
7. Photodynamic therapy (PDT) using HPPH for the treatment of precancerous lesions associated with Barrett's esophagus.
Nava HR; Allamaneni SS; Dougherty TJ; Cooper MT; Tan W; Wilding G; Henderson BW
Lasers Surg Med; 2011 Sep; 43(7):705-12. PubMed ID: 22057498
[TBL] [Abstract][Full Text] [Related]
8. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
[TBL] [Abstract][Full Text] [Related]
9. Chlorophyll-a analogues conjugated with aminobenzyl-DTPA as potential bifunctional agents for magnetic resonance imaging and photodynamic therapy.
Li G; Slansky A; Dobhal MP; Goswami LN; Graham A; Chen Y; Kanter P; Alberico RA; Spernyak J; Morgan J; Mazurchuk R; Oseroff A; Grossman Z; Pandey RK
Bioconjug Chem; 2005; 16(1):32-42. PubMed ID: 15656573
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of raltitrexed in patients with advanced solid tumours.
Blair EY; Rivory LP; Clarke SJ; McLachlan AJ
Br J Clin Pharmacol; 2004 Apr; 57(4):416-26. PubMed ID: 15025739
[TBL] [Abstract][Full Text] [Related]
11. [Local curative treatment of superficial adenocarcinoma in Barrett's esophagus. First results of photodynamic therapy with a new photosensitizer].
Etienne J; Dorme N; Bourg-Heckly G; Raimbert P; Fékété F
Bull Acad Natl Med; 2000; 184(8):1731-44; discussion 1744-7. PubMed ID: 11471391
[TBL] [Abstract][Full Text] [Related]
12. Clinical experience of patients undergoing photodynamic therapy for Barrett's dysplasia or cancer.
Wolfsen HC; Hemminger LL; Wallace MB; Devault KR
Aliment Pharmacol Ther; 2004 Nov; 20(10):1125-31. PubMed ID: 15569115
[TBL] [Abstract][Full Text] [Related]
13. A Phase I Study of Light Dose for Photodynamic Therapy Using 2-[1-Hexyloxyethyl]-2 Devinyl Pyropheophorbide-a for the Treatment of Non-Small Cell Carcinoma In Situ or Non-Small Cell Microinvasive Bronchogenic Carcinoma: A Dose Ranging Study.
Dhillon SS; Demmy TL; Yendamuri S; Loewen G; Nwogu C; Cooper M; Henderson BW
J Thorac Oncol; 2016 Feb; 11(2):234-41. PubMed ID: 26718878
[TBL] [Abstract][Full Text] [Related]
14. The pharmacokinetic behavior of the photosensitizer meso-tetra-hydroxyphenyl-chlorin in mice and men.
Triesscheijn M; Ruevekamp M; Out R; Van Berkel TJ; Schellens J; Baas P; Stewart FA
Cancer Chemother Pharmacol; 2007 Jun; 60(1):113-22. PubMed ID: 17009028
[TBL] [Abstract][Full Text] [Related]
15. Pre-clinical compartmental pharmacokinetic modeling of 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a (HPPH) as a photosensitizer in rat plasma by validated HPLC method.
Krishna KV; Saha RN; Puri A; Viard M; Shapiro BA; Dubey SK
Photochem Photobiol Sci; 2019 May; 18(5):1056-1063. PubMed ID: 30608096
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
Joerger M; Huitema AD; Meenhorst PL; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 2005 May; 55(5):488-96. PubMed ID: 15726371
[TBL] [Abstract][Full Text] [Related]
17. Murine pharmacokinetics and antitumor efficacy of the photodynamic sensitizer 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a.
Bellnier DA; Henderson BW; Pandey RK; Potter WR; Dougherty TJ
J Photochem Photobiol B; 1993 Sep; 20(1):55-61. PubMed ID: 8229470
[TBL] [Abstract][Full Text] [Related]
18. delta-Aminolevulinic acid and blue light photodynamic therapy for treatment of multiple basal cell carcinomas in two patients with nevoid basal cell carcinoma syndrome.
Itkin A; Gilchrest BA
Dermatol Surg; 2004 Jul; 30(7):1054-61. PubMed ID: 15209801
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of a tri-glucoconjugated 5,10,15-(meta)-trihydroxyphenyl-20-phenyl porphyrin photosensitizer for PDT. A single dose study in the rat.
Desroches MC; Bautista-Sanchez A; Lamotte C; Labeque B; Auchère D; Farinotti R; Maillard P; Grierson DS; Prognon P; Kasselouri A
J Photochem Photobiol B; 2006 Oct; 85(1):56-64. PubMed ID: 16765603
[TBL] [Abstract][Full Text] [Related]
20. Mesoscopic fluorescence tomography of a photosensitizer (HPPH) 3D biodistribution in skin cancer.
Ozturk MS; Rohrbach D; Sunar U; Intes X
Acad Radiol; 2014 Feb; 21(2):271-80. PubMed ID: 24439340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
